Bromocriptine Mesylate

This page contains recent news articles, when available, and an overview of Bromocriptine Mesylate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Bromocriptine Mesylate (when available)

Pharmacology and use:
Bromocriptine is an ergoline derivitave dopamine agonist that is used in the treatment of amenorrhea, female infertility, abnormal discharge of breast milk, hypogonadism, Parkinson's disease, and acromegaly. Bromocriptine produces its therapeutic effect in the treatment of Parkinson's disease, a clinical condition characterized by a progressive deficiency in dopamine synthesis in the substantia nigra, by directly stimulating the dopamine receptors in the corpus striatum. For treatment of idiopathic or postencephalitic Parkinson's disease, dysfunctions associated with hyperprolactinemia and in the treatment of acromegaly

Mechanism Of Action:
Bromocriptine acts by directly stimulating the dopamine receptors in the corpus striatum.

News Articles on Bromocriptine

Cadila Health gets US nod for bromocriptine mesylate  -  Aug 1, 2008
MUMBAI (Reuters) - Drug maker Cadila Healthcare Ltd (CADI.BO) said on Friday it received the US Food and Drug Administration approval for its generic ... Reuters

Bromocriptine mesylate or cabergoline for infertility  -  Mar 21, 2008
Bromocriptine and cabergoline reduce the body's amount of prolactin, a hormone produced by the pituitary gland. Excess prolactin makes a woman stop ... WebMD

… on Cycloset(TM) (A Quick Release Formulation of Bromocriptine...  -  Jun 18, 2007
...entitled, "Effects of Timed Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Administration of Safety, Cardiovascular Event Rate, ... Free with registration - PR Newswire - AccessMyLibrary.com

Press Release: Phase IIIb Clinical Data Validate the Overall and …  -  Jun 23, 2007
Update Bromocriptine Mesylate Tablets (Cycloset™) By William T. Elliott ... release formulation by VeroScience LLC as Cycloset™. ... Pay-Per-View - PR Newswire - HighBeam Research

Press Release: Phase IIIb Clinical Data Validate the Overall and …  -  Jun 23, 2007
Update Bromocriptine Mesylate Tablets (Cycloset™) By William T. Elliott ... release formulation by VeroScience LLC as Cycloset™. ... Pay-Per-View - PR Newswire Europe - HighBeam Research

Phase IIIb Clinical Data Validate the Overall and Cardiovascular...  -  Jun 23, 2007
...the overall and cardiovascular safety of Cycloset(TM) (A quick release formulation of bromocriptine mesylate) in subjects with type 2 diabetes. ... RedOrbit

Press Release: VeroScience Late-Breaking Abstract on Cycloset(TM) (A ...  -  Jun 18, 2007
VeroScience Late-Breaking Abstract on Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American ... Pay-Per-View - PR Newswire - HighBeam Research

Press Release: Magnetic Mini Sweeper With Quick Release Conveniently …  -  Jul 1, 2008
PR Newswire; June 18, 2007 ; 700+ words ... ... abstract, entitled, "Effects of Timed Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) ... Pay-Per-View - PR Newswire - HighBeam Research

ADA: New Drug Cycloset Improves Glucose Control and Reduces CVD …  -  Jun 27, 2007
A quick release formulation of bromocriptine mesylate in patients with type 2 diabetes improves glycemic control and reduces diabetic cardiovascular ... Diabetes In Control

Phase IIIb Clinical Data Validate Overall, Cardiovascular Safety...  -  Jun 25, 2007
...supporting the overall and cardiovascular safety of Cycloset (A quick release formulation of bromocriptine mesylate) in subjects with type 2 diabetes. ... emaxhealth.com

Gigantism - Symptoms, Diagnosis, Treatment of Gigantism - NY Times …  -  Mar 18, 2008
Dopamine agonists (bromocriptine mesylate, cabergoline) have also been used to reduce growth hormone secretion, but these are generally less effective. ... New York Times

33% rise in Zydus Cadila net  -  Oct 24, 2008
During the quarter, the company received approvals from the USFDA for Bromocriptine Mesylate capsules and Ramipril capsules. The group filed five additional ... Hindu Business Line

Wythe Therapeutics and VeroScience Announce Worldwide License for …  -  Jun 26, 2006
Vero is seeking approval to market Cycloset , a patented novel oral formulation of bromocriptine mesylate, for the treatment of Type-2 Diabetes. ... Free with registration - M2 Presswire - AccessMyLibrary.com

Illinois Administrative Code - 86 Ill. Adm. Code 530.110 Covered …  -  Aug 10, 2005
Pharmaceutical Assistance Program as covered prescription drugs: 1) Anticholinergics 2) Amantadine 3) Bromocriptine Mesylate 4) Carbidopa 5) Levodopa 6) ... Pay-Per-View - Illinois Administrative Code - Loislaw

Mylan Reports Fiscal 2005 Earnings Per Diluted Share of $0.74 -- …  -  May 12, 2005
In fiscal 2006 to date, the Company has received final ANDA approval for bromocriptine mesylate capsules and anagrelide hydrochloride capsules and tentative ... $4.95 - PR Newswire - ECNext

Press Release: Mylan Reports Fiscal 2005 Earnings Per Diluted Share...  -  May 12, 2005
In fiscal 2006 to date, the Company has received final ANDA approval for bromocriptine mesylate capsules and anagrelide hydrochloride capsules and tentative ... Pay-Per-View - PR Newswire - HighBeam Research

Quick-release bromocriptine has favorable cardiovascular safety...  -  Aug 1, 2007
Phase IIIb clinical data validate the overall and cardiovascular safety profile of Cycloset (a quick release formulation of bromocriptine mesylate) in ... Free with registration - Formulary - AccessMyLibrary.com

Correction.(Correction notice) | Article from Internal Medicine News...  -  Jun 1, 2008
Cycloset, a quick-release oral formulation of bromocriptine mesylate, was recently approved by the Food and Drug Administration as a treatment for type 2 ... Pay-Per-View - Internal Medicine News - HighBeam Research

When Lying Still Is Only a Dream  -  Mar 4, 2007
The dopaminergic agonists pergolide (Permax), ropinirole (Requip), pramipexole (Mirapex), and bromocriptine mesylate (Alti-Bromocriptine, Apo-Bromocriptine, ... Sleep Review

Reassuring CV safety from Ph IIIb Cycloset trial.(Brief article)(Clini...  -  Jul 2, 2007
...supporting the overall and cardiovascular safety of Cycloset, a quick release formulation of bromocriptine mesylate, in subjects with type 2 diabetes. ... Free with registration - Pharma Marketletter - AccessMyLibrary.com

Hyman & Armstrong, PSC v. Gunderson, No. 2006-SC-000175-DG (Ky. …  -  Apr 24, 2008
Because Mary did not want to breastfeed, Mary's obstetrician, Dr. Lyman Armstrong, prescribed the drug Parlodel (bromocriptine mesylate) to stop lactation. ... $2.95 - Kentucky Supreme Court - VersusLaw

Chemicals, raw materials & specialties.(BROMOCRESOL GREEN, …  -  Dec 1, 2007
BROMOCRIPTINE MESYLATE RONAS CHEMICALS IND. CO., LTD. * SPECTRUM CHEMICAL MFG. CORP. [telephone] 800-378-7899, ask for catalog www.spectrumchemical.com ... $4.95 - Chemical Week - ECNext

Kentucky Reports - HYMAN & ARMSTRONG, PSC v. GUNDERSON, …  -  Apr 24, 2008
Because Mary did not want to breastfeed, Mary's obstetrician, Dr. Lyman Armstrong, prescribed the drug Parlodel (bromocriptine mesylate) to stop lactation. ... Pay-Per-View - Kentucky Reports - Loislaw

COMUNICADO: Los datos clínicos en Fase IIIb validan el perfil general...  -  Jun 23, 2007
Effects of Timed Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Administration on Safety, Cardiovascular Event Rate, and Glycemic ... elEconomista.es

Brand Names/Synonyms:
Bromocriptine Mesylate is also known by the following brand names and/or synonymsAlti-Bromocriptine; Apo-Bromocriptine; Bromergocryptine; Bromocriptin; Bromocriptina [Inn-Spanish]; Bromocriptine; Bromocriptine Mesylate; Bromocriptine Methanesulfonate; Bromocriptine [Usan:Ban:Inn]; Bromocriptinum [Inn-Latin]; Bromocryptine; Bromocryptine Mesylate; Bromoergocriptine; Bromoergocryptine; CB 154; CB-154; CCRIS 3244; Parlodel; Parlodel Snaptabs

Drug Category:
Bromocriptine Mesylate is categorized under the following by the FDA: Antiparkinson Agents; Antidyskinetics; Unclassified Therapeutic Agents (92:00.00); ATC:G02CB01; ATC:N04BC01

Dosage Forms:
CAPSULE

Absorption:
Not Available

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
Not Available

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.